MCID: EMB004
MIFTS: 57

Embryonal Carcinoma malady

Categories: Rare diseases, Cancer diseases, Fetal diseases

Aliases & Classifications for Embryonal Carcinoma

Aliases & Descriptions for Embryonal Carcinoma:

Name: Embryonal Carcinoma 12 50 56 14 69
Embryonal Neoplasm 12 69
Embryonal Cancer 12 14
Primary Extragonadal Embryonal Carcinoma 12
Extragonadal Embryonal Carcinoma 69
Carcinoma, Embryonal 42
Carcinoma Embryonal 52
Cancer, Embryonal 69
Cancer Embryonal 52
Embryo Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3308 DOID:688
SNOMED-CT 64 189843003 28047004
Orphanet 56 ORPHA180226
ICD10 via Orphanet 34 C22.7 C71.9
MESH via Orphanet 43 D018236
UMLS via Orphanet 70 C0206659

Summaries for Embryonal Carcinoma

NIH Rare Diseases : 50 embryonal carcinoma is a type of testicular cancer, which is cancer that starts in the testicles, the male reproductive glands located in the scrotum. it most often develops in young and middle-aged men. it tends to grow rapidly and spread outside the testicle. embryonal carcinomas are classified as nonseminoma germ cell tumors. most testicular cancers grow from germ cells, the cells that make sperm. germ cell tumors are broadly divided into seminomas and nonseminomas because each type has a different prognosis and treatment regimen. nonseminomas, which are more common, tend to grow more quickly than seminomas. nonseminoma tumors are often made up of more than one type of cell, and are identified according to the different cell types. last updated: 2/1/2012

MalaCards based summary : Embryonal Carcinoma, also known as embryonal neoplasm, is related to ovarian embryonal carcinoma and childhood ovarian embryonal carcinoma. An important gene associated with Embryonal Carcinoma is POU5F1 (POU Class 5 Homeobox 1), and among its related pathways/superpathways are Developmental Biology and Human Embryonic Stem Cell Pluripotency. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include ovary, testes and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and mortality/aging

Disease Ontology : 12 An embryonal cancer that is a type of germ cell tumour that is located in the ovaries or located in the testes.

Wikipedia : 71 Embryonal carcinoma is a relatively uncommon type of germ cell tumour that occurs in the ovaries and... more...

Related Diseases for Embryonal Carcinoma

Diseases related to Embryonal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 ovarian embryonal carcinoma 12.2
2 childhood ovarian embryonal carcinoma 12.1
3 intratubular embryonal carcinoma 12.0
4 central nervous system embryonal carcinoma 12.0
5 adult central nervous system embryonal carcinoma 11.9
6 germ cell and embryonal cancer 11.9
7 non-central nervous system-localized embryonal carcinoma 11.8
8 endodermal sinus tumor 11.6
9 teratocarcinoma 11.6
10 embryonal testis carcinoma 11.6
11 testicular germ cell tumor 11.1
12 childhood embryonal testis carcinoma 11.0
13 childhood teratocarcinoma of the testis 10.8
14 pediatric cns embryonal cell carcinoma 10.8
15 polyembryoma 10.7
16 hemihyperplasia, isolated 10.7
17 trophoblastic neoplasm 10.7
18 neuronitis 10.3
19 fallopian tube leiomyoma 10.3 AFP POU5F1 TNFRSF8
20 anterior optic tract meningioma 10.3 AFP TNFRSF8
21 esophagus liposarcoma 10.3 AFP POU5F1
22 toxascariasis 10.2 AFP POU5F1 SOX2
23 solar retinopathy 10.2 RARA RARB RARS
24 paranasal sinus cancer 10.2 NES POU5F1 TNFRSF8
25 pediatric liposarcoma 10.2 AFP POU5F1 SOX2 TNFRSF8
26 hypothalamic neoplasm 10.2 NES SOX2
27 subendocardial myocardial infarction 10.2 AFP POU5F1 SOX2 TNFRSF8
28 nutritional deficiency disease 10.2 AFP TNFRSF8
29 childhood kidney cell carcinoma 10.2 AFP NES POU5F1 SOX2
30 atopic dermatitis 10.2 AFP POU5F1 SOX2
31 cystinosis 10.2 BMP4 GDF3 RARB SOX2
32 nonossifying fibromyxoid tumor 10.1 AFP TNFRSF8
33 central nervous system disease 10.1 AFP CRABP1 POU5F1 TDGF1
34 seminoma 10.0
35 bleeding disorder, platelet-type, 18 10.0 CRABP1 CRABP2 RARA RARB RARS
36 teratoma 9.9
37 prostatitis 9.7
38 gonadoblastoma 9.7
39 leukemia 9.7
40 choriocarcinoma 9.7
41 neurodermatitis 9.7 CRABP1 FGF4 NR6A1 POU5F1 RARA RARB
42 androgen insensitivity 9.6
43 male infertility 9.6
44 infertility 9.6
45 mediastinitis 9.6
46 precocious puberty 9.6
47 hypoxia 9.6
48 mixed germ cell tumor 9.6
49 ovarian cancer 9.5
50 cervicitis 9.5

Graphical network of the top 20 diseases related to Embryonal Carcinoma:



Diseases related to Embryonal Carcinoma

Symptoms & Phenotypes for Embryonal Carcinoma

GenomeRNAi Phenotypes related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.4 AFP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.4 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.4 POU5F1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.4 POU5F1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.4 POU5F1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.4 AFP NDN POU5F1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.4 AFP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.4 POU5F1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.4 AFP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.4 POU5F1

MGI Mouse Phenotypes related to Embryonal Carcinoma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.31 AFP BMP4 CRABP1 CRABP2 FGF4 GATA4
2 embryo MP:0005380 10.29 BMP4 FGF4 GATA4 GDF3 LIF NR6A1
3 endocrine/exocrine gland MP:0005379 10.24 POU5F1 RARA RARB RARG SOX2 TNFRSF8
4 digestive/alimentary MP:0005381 10.18 BMP4 GATA4 LIF NR6A1 POU5F1 RARA
5 integument MP:0010771 10.06 BMP4 GATA4 LIF NDN POU5F1 RARG
6 nervous system MP:0003631 10.06 BMP4 GATA4 LIF NDN NR6A1 POU5F1
7 limbs/digits/tail MP:0005371 10.03 CRABP1 CRABP2 FGF4 GATA4 NR6A1 RARA
8 normal MP:0002873 10.03 BMP4 CRABP1 FGF4 GATA4 GDF3 NDN
9 hearing/vestibular/ear MP:0005377 10.02 BMP4 CRABP1 CRABP2 RARA RARB RARG
10 muscle MP:0005369 9.91 BMP4 GATA4 LIF NDN RARA RARB
11 reproductive system MP:0005389 9.9 AFP BMP4 FGF4 GATA4 LIF NR6A1
12 respiratory system MP:0005388 9.61 BMP4 FGF4 GATA4 LIF NDN RARA
13 skeleton MP:0005390 9.28 LIF NR6A1 RARA BMP4 FGF4 GATA4

Drugs & Therapeutics for Embryonal Carcinoma

Drugs for Embryonal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 443)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 33069-62-4 36314
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
5
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
6
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
9 Chorionic Gonadotropin Phase 4
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
12 Albumin-Bound Paclitaxel Phase 4,Phase 2,Phase 3,Phase 1
13 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
15 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1
18 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1
19 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23
Lactitol Phase 4,Phase 1,Phase 2 585-86-4 3871
24 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
25 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Coagulants Phase 4
27 Fibrin Tissue Adhesive Phase 4
28 Hemostatics Phase 4,Phase 1
29 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antihypertensive Agents Phase 4,Phase 3
31 insulin Phase 4,Phase 2,Phase 1
32 Insulin, Globin Zinc Phase 4,Phase 2,Phase 1
33 Hypoglycemic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
34 Vasodilator Agents Phase 4
35
Bleomycin Approved Phase 2, Phase 3 11056-06-7 5360373
36
Cisplatin Approved Phase 2, Phase 3, Phase 1 15663-27-1 84093 441203 2767
37
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
38
Lenograstim Approved Phase 2, Phase 3, Phase 1 135968-09-1
39
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
40
Mechlorethamine Approved Phase 3,Phase 1,Phase 2 51-75-2 4033
41
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
42
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3
43
Fluorouracil Approved Phase 2, Phase 3, Phase 1 51-21-8 3385
44
Levoleucovorin Approved Phase 2, Phase 3, Phase 1 68538-85-2
45
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 83150-76-9 383414 6400441
46
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
47
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
48
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
49
Mesna Approved Phase 3,Phase 1,Phase 2 3375-50-6 598
50
Palivizumab Approved, Investigational Phase 3 188039-54-5

Interventional clinical trials:

(show top 50) (show all 806)
id Name Status NCT ID Phase
1 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Unknown status NCT00294177 Phase 4
2 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
3 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
4 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
5 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
6 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4
7 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
8 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
9 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
10 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
11 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
12 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
13 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
14 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
15 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
16 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
17 Combination Chemotherapy in Treating Men With Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3
18 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Unknown status NCT00104676 Phase 3
19 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3
20 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
21 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
22 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3
23 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer Completed NCT00003941 Phase 3
24 Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Completed NCT00002596 Phase 3
25 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
26 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
27 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
28 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
29 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
30 A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies Completed NCT02829775 Phase 2, Phase 3
31 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
32 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3
33 Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases Completed NCT00540969 Phase 3
34 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
35 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
36 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3
37 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET-CT Scan Completed NCT03136328 Phase 3
38 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3
39 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3
40 High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors Completed NCT00037869 Phase 3
41 Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease Completed NCT00690430 Phase 3
42 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3
43 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3
44 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3
45 Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3
46 Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Recruiting NCT02586350 Phase 2, Phase 3
47 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3
48 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3
49 ImmuniCell® in Patients With Advanced Cancers Recruiting NCT02459067 Phase 2, Phase 3
50 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3

Search NIH Clinical Center for Embryonal Carcinoma

Cochrane evidence based reviews: carcinoma, embryonal

Genetic Tests for Embryonal Carcinoma

Anatomical Context for Embryonal Carcinoma

MalaCards organs/tissues related to Embryonal Carcinoma:

39
Ovary, Testes, Brain, Testis, Bone, Lung, Smooth Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Embryonal Carcinoma:

18
The Ovaries Or

Publications for Embryonal Carcinoma

Articles related to Embryonal Carcinoma:

(show top 50) (show all 353)
id Title Authors Year
1
Whole brain radiotherapy with volumetric-modulated arc therapy for pediatric intracranial embryonic carcinoma prevents permanent alopecia. ( 28042910 )
2017
2
Autocrine glutamatergic transmission for the regulation of embryonal carcinoma stem cells. ( 27322683 )
2016
3
MicroRNA-29c overexpression inhibits proliferation and promotes apoptosis and differentiation in P19 embryonal carcinoma cells. ( 26484393 )
2016
4
Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells. ( 27861613 )
2016
5
SOX2 is essential for in vivo reprogramming of seminoma-like TCam-2 cells to an embryonal carcinoma-like fate. ( 27283990 )
2016
6
Endobronchial Embryonal Carcinoma. ( 27623424 )
2016
7
Production of stable GFP-expressing neural cells from P19 embryonal carcinoma stem cells. ( 28013042 )
2016
8
Calmidazolium chloride inhibits growth of murine embryonal carcinoma cells, a model of cancer stem-like cells. ( 27247146 )
2016
9
Immature Teratoma with Embryonal Carcinoma; a Rare Malignant Mixed Germ Cell Tumor in a 13-Year-Old Girl. ( 26870146 )
2016
10
Growth and Differentiation Factor 3 Is Transcriptionally Regulated by OCT4 in Human Embryonic Carcinoma Cells. ( 27803451 )
2016
11
Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. ( 26453693 )
2016
12
Case report: Malignant germ cell tumour with predominant embryonal carcinoma component in a dysgenetic gonad. ( 27773100 )
2016
13
Testis peritubular myoid cells increase their motility and express matrix-metalloproteinase 9 (MMP-9) after interaction with embryonal carcinoma cells. ( 26711538 )
2016
14
The miR-134 attenuates the expression of transcription factor FOXM1 during pluripotent NT2/D1 embryonal carcinoma cell differentiation. ( 25447206 )
2015
15
CRISPR/Cas9-Mediated Genomic Deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 Gene in Murine P19 Embryonal Carcinoma Cells Results in Low Sensitivity to Botulinum Neurotoxin Type C. ( 26177297 )
2015
16
Epigenetic role of CCAAT box-binding transcription factor NF-Y on ID gene family in human embryonic carcinoma cells. ( 26509926 )
2015
17
Pulmonary artery stenosis due to embryonal carcinoma with primary mediastinal location. ( 25754058 )
2015
18
Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide. ( 26102294 )
2015
19
BMP Inhibition in Seminomas Initiates Acquisition of Pluripotency via NODAL Signaling Resulting in Reprogramming to an Embryonal Carcinoma. ( 26226633 )
2015
20
Human embryonal carcinoma cells in serum-free conditions as an in vitro model system of neural differentiation. ( 25802994 )
2015
21
Metastatic embryonal carcinoma mimicking locally advanced non-small cell lung cancer. ( 25742895 )
2015
22
Embryonal Carcinoma in Cryptorchid Abdominal Testis of an Infant. ( 26137335 )
2015
23
Primary pure and nonsecreting embryonal carcinoma of the anterior third ventricle: a case report. ( 25832366 )
2015
24
Downregulation of miR-320a/383-sponge-like long non-coding RNA NLC1-C (narcolepsy candidate-region 1 genes) is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation. ( 26539909 )
2015
25
Transcription factor NF-Y inhibits cell growth and decreases SOX2 expression in human embryonal carcinoma cell line NT2/D1. ( 25756534 )
2015
26
Inhibition of testicular embryonal carcinoma cell tumorigenicity by peroxisome proliferator-activated receptor-I^/I'- and retinoic acid receptor-dependent mechanisms. ( 26431381 )
2015
27
Aggressive multimodal therapy may prolong disease-free survival in recurrent primary retroperitoneal embryonal carcinoma. ( 25799960 )
2015
28
NgR1 Expressed in P19 Embryonal Carcinoma Cells Differentiated by Retinoic Acid Can Activate STAT3. ( 25729271 )
2015
29
Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cells. ( 26025920 )
2015
30
The knockdown of H19lncRNA reveals its regulatory role in pluripotency and tumorigenesis of human embryonic carcinoma cells. ( 26415227 )
2015
31
Dickkopf-3 alters the morphological response to retinoic acid during neuronal differentiation of human embryonal carcinoma cells. ( 24909558 )
2014
32
Transcriptional activation of OCT4 by the ETS transcription factor PEA3 in NCCIT human embryonic carcinoma cells. ( 24983502 )
2014
33
Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells. ( 25208472 )
2014
34
Gonadotrophin-independent precocious puberty associated with later diagnosis of testicular embryonal carcinoma. ( 25012595 )
2014
35
Aza-deoxycytidine induces apoptosis or differentiation via DNMT3B and targets embryonal carcinoma cells but not their differentiated derivatives. ( 24603304 )
2014
36
Role of SOX2 in the etiology of embryonal carcinoma, based on analysis of the NCCIT and NT2 cell lines. ( 24404135 )
2014
37
AP-1-mediated expression of brain-specific class IVa I^-tubulin in P19 embryonal carcinoma cells. ( 25649943 )
2014
38
miR-27 negatively regulates pluripotency-associated genes in human embryonal carcinoma cells. ( 25369332 )
2014
39
Mixed ovarian germ cell tumor composed of immature teratoma, yolk sac tumor and embryonal carcinoma. ( 25518772 )
2014
40
Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. ( 23378141 )
2014
41
Transcriptional regulation of OCT4 by the ETS transcription factor ESE-1 in NCCIT human embryonic carcinoma cells. ( 24971534 )
2014
42
microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells. ( 24462707 )
2014
43
Seminoma and embryonal carcinoma footprints identified by analysis of integrated genome-wide epigenetic and expression profiles of germ cell cancer cell lines. ( 24887064 )
2014
44
Differential expression of ETS family transcription factors in NCCIT human embryonic carcinoma cells upon retinoic acid-induced differentiation. ( 24694612 )
2014
45
DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. ( 23287532 )
2013
46
Comparative SRY incorporation on the regulatory regions of pluripotency/differentiation genes in human embryonic carcinoma cells after retinoic acid induction. ( 23361361 )
2013
47
Heterochromatin protein 1I^ overexpression in P19 embryonal carcinoma cells elicits spontaneous differentiation into the three germ layers. ( 23313480 )
2013
48
Allelotyping analysis suggesting a consecutive progression from intratubular germ cell neoplasia to seminoma and then to embryonal carcinoma of the adult testis. ( 23938161 )
2013
49
Spontaneous nonmetastatic choriocarcinoma, yolk sac carcinoma, embryonal carcinoma, and teratoma in the testes of a swiss albino mouse. ( 23104768 )
2013
50
MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. ( 23625774 )
2013

Variations for Embryonal Carcinoma

Expression for Embryonal Carcinoma

Search GEO for disease gene expression data for Embryonal Carcinoma.

Pathways for Embryonal Carcinoma

Pathways related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 FGF4 NR6A1 POU5F1 RARA RARB RARG
2
Show member pathways
12.42 BMP4 FGF4 GATA4 POU5F1 SOX2 TDGF1
3
Show member pathways
12.35 BMP4 GATA4 GDF3 POU5F1 RARB RARG
4 12.1 AFP BMP4 NR6A1 POU5F1 SOX2 TDGF1
5 12.01 BMP4 LIF POU5F1 SOX2
6 11.95 BMP4 GATA4 LIF NDN RARA
7 11.83 BMP4 FGF4 GATA4 TDGF1
8 11.82 LIF NDN SOX2
9
Show member pathways
11.79 NR6A1 RARA RARB RARG
10 11.73 BMP4 FGF4 NES SOX2
11 11.54 BMP4 GATA4 POU5F1 SOX2
12
Show member pathways
11.47 NR6A1 POU5F1 SOX2 TDGF1
13
Show member pathways
11.47 CRABP1 CRABP2 RARA RARB RARG
14 11.4 AFP BMP4 FGF4 GATA4 LIF NES
15 11.33 CRABP2 RARA RARB RARG
16 11.28 RARA RARB RARG
17 11.11 BMP4 CRABP2 LIF RARG
18 11 CRABP1 CRABP2 RARA RARB RARG
19 10.69 FGF4 NR6A1 POU5F1 SOX2
20
Show member pathways
10.63 BMP4 POU5F1 SOX2

GO Terms for Embryonal Carcinoma

Cellular components related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.32 CRABP2 GATA4 NDN NR6A1 POU5F1 RARA

Biological processes related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 BMP4 FGF4 LIF POU5F1 RARA RARG
2 positive regulation of cell proliferation GO:0008284 9.98 BMP4 FGF4 LIF RARA RARB RARG
3 regulation of gene expression GO:0010468 9.95 BMP4 FGF4 POU5F1 RARG SOX2
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.92 NR6A1 RARA RARB RARG
5 negative regulation of cell proliferation GO:0008285 9.91 BMP4 LIF NDN RARA RARB RARG
6 positive regulation of neuron differentiation GO:0045666 9.85 BMP4 RARA RARB
7 multicellular organism growth GO:0035264 9.85 RARA RARB RARG
8 neural tube closure GO:0001843 9.85 BMP4 RARA RARG
9 somatic stem cell population maintenance GO:0035019 9.83 POU5F1 SOX2 TDGF1
10 SMAD protein signal transduction GO:0060395 9.83 AFP BMP4 GDF3
11 ureteric bud development GO:0001657 9.79 BMP4 RARA RARB
12 endoderm development GO:0007492 9.76 BMP4 GATA4 GDF3
13 bone development GO:0060348 9.76 BMP4 RARA RARB RARG
14 outflow tract septum morphogenesis GO:0003148 9.73 BMP4 RARA RARB
15 negative regulation of chondrocyte differentiation GO:0032331 9.71 BMP4 RARB RARG
16 negative regulation of myoblast differentiation GO:0045662 9.7 BMP4 GDF3
17 retinoic acid receptor signaling pathway GO:0048384 9.7 RARA RARB RARG
18 response to vitamin A GO:0033189 9.69 GATA4 RARA
19 face development GO:0060324 9.69 RARA RARG
20 cardiac right ventricle morphogenesis GO:0003215 9.68 BMP4 GATA4
21 endocardial cushion development GO:0003197 9.67 BMP4 GATA4
22 embryonic eye morphogenesis GO:0048048 9.67 RARB RARG
23 regulation of myelination GO:0031641 9.67 RARA RARB RARG
24 positive regulation of programmed cell death GO:0043068 9.66 RARB RARG
25 glomerular visceral epithelial cell development GO:0072015 9.66 BMP4 PODXL
26 epithelium development GO:0060429 9.65 BMP4 RARG
27 embryonic camera-type eye development GO:0031076 9.65 NES RARA RARG
28 cranial suture morphogenesis GO:0060363 9.64 BMP4 FGF4
29 retinal pigment epithelium development GO:0003406 9.64 RARB RARG
30 endodermal cell fate specification GO:0001714 9.63 POU5F1 SOX2
31 chondroblast differentiation GO:0060591 9.63 FGF4 RARA
32 ventricular cardiac muscle cell differentiation GO:0055012 9.62 RARA RARB
33 regulation of cell fate commitment GO:0010453 9.61 BMP4 GDF3
34 trachea cartilage development GO:0060534 9.6 RARA RARG
35 negative regulation of cartilage development GO:0061037 9.58 RARA RARB RARG
36 embryonic hindlimb morphogenesis GO:0035116 9.56 BMP4 FGF4 RARB RARG
37 growth plate cartilage development GO:0003417 9.5 RARA RARB RARG
38 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.36 BMP4 FGF4 GATA4 LIF NDN NR6A1
39 steroid hormone mediated signaling pathway GO:0043401 9.35 BMP4 NR6A1 RARA RARB RARG
40 glandular epithelial cell development GO:0002068 9.33 RARA RARB RARG
41 regulation of transcription, DNA-templated GO:0006355 10.35 CRABP2 GATA4 NDN NR6A1 POU5F1 RARA
42 multicellular organism development GO:0007275 10.18 BMP4 CRABP1 FGF4 GDF3 LIF NES
43 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.11 BMP4 NR6A1 POU5F1 RARA RARB RARG
44 transcription from RNA polymerase II promoter GO:0006366 10.08 GATA4 NDN NR6A1 POU5F1 SOX2
45 negative regulation of apoptotic process GO:0043066 10.07 BMP4 FGF4 RARA RARB RARG TDGF1

Molecular functions related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.91 GATA4 NR6A1 POU5F1 RARA RARB RARG
2 sequence-specific DNA binding GO:0043565 9.8 GATA4 NR6A1 POU5F1 RARA RARB RARG
3 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.71 GATA4 RARA RARB RARG
4 growth factor activity GO:0008083 9.55 BMP4 FGF4 GDF3 LIF TDGF1
5 retinoid X receptor binding GO:0046965 9.51 RARB RARG
6 retinoic acid binding GO:0001972 9.5 CRABP1 CRABP2 RARA
7 miRNA binding GO:0035198 9.49 POU5F1 SOX2
8 retinol binding GO:0019841 9.48 CRABP1 CRABP2
9 retinoid binding GO:0005501 9.46 CRABP1 CRABP2
10 retinal binding GO:0016918 9.43 CRABP1 CRABP2
11 steroid hormone receptor activity GO:0003707 9.26 NR6A1 RARA RARB RARG
12 retinoic acid receptor activity GO:0003708 8.8 RARA RARB RARG

Sources for Embryonal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....